Study:
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Rationale:
n/a
Purpose:
This study is being conducted to learn about the safety and risks of using OncoVEXGM-CSF to
treat patients with melanoma and to see if OncoVEXGM CSF can destroy these tumours compared
to GM-CSF. This study may provide information on the usefulness of OncoVEXGM-CSF as a
future treatment for melanoma. This study may also provide information on the safety and
usefulness of GM-CSF as compared to OncoVEXGM-CSF as a treatment for melanoma.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Melanoma |
Biological: OncoVEXGM-CSF (talimogene laherparepvec)
Biological: GM-CSF |
Phase 3 |
Verified by
BioVex Limited
June, 2012
Sponsored by: BioVex Limited
Information provided by: BioVex Limited
ClinicalTrials.gov identifier: NCT00769704
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Foundation, Taussig Cancer Center
Cleveland, Ohio 44195
United States
MD., Study Director